Previous studies have specifically examined the preclinical efficacy of LSD1, HDAC, EZH2, and BET inhibitors on MCC cell lines and mouse studies to understand whether these agents hold the potential for clinical translation. The gene discussed is EZH2; the disease is Merkel cell skin cancer.